HBOT for Fibromyalgia: What the Evidence Shows and Why It Matters

Fibromyalgia occupies an uncomfortable position in medicine. It is a condition that affects an estimated two to four percent of the population, causes significant and often debilitating symptoms, and has been the subject of decades of research. Yet it remains poorly understood, inconsistently treated, and frequently dismissed by clinicians who are uncertain what to do with a diagnosis that does not fit neatly into conventional disease categories.

For people living with fibromyalgia, this dismissal is one of the most frustrating aspects of the condition. The symptoms are real. The impact on quality of life is real. The inadequacy of most available treatments is also real. It is in this context that interest in hyperbaric oxygen therapy has grown, and where the research that has emerged over the past decade deserves careful attention.

Understanding Fibromyalgia: The Mechanism That Changes Everything

For a long time, fibromyalgia was treated as a musculoskeletal condition, a disorder of the muscles and soft tissues that caused widespread pain. This framing was never entirely satisfying, and the research of the past two decades has largely replaced it with a different understanding.

Fibromyalgia is now understood primarily as a disorder of central sensitisation. The problem is not in the muscles themselves but in the way the central nervous system processes pain signals. In people with fibromyalgia, the pain-processing pathways of the brain and spinal cord are dysregulated in ways that amplify pain signals, lower the threshold at which stimuli are perceived as painful, and generate pain in the absence of the tissue damage that would normally be required to explain it.

This reframing has important implications. It means that treatments targeting peripheral tissue, anti-inflammatories, muscle relaxants, local injections, are addressing the wrong level of the problem. It also means that the relevant question for any potential treatment is not whether it reduces peripheral inflammation but whether it can influence the central nervous system mechanisms that are driving the condition.

This is precisely where HBOT becomes relevant.

What Brain Imaging Has Revealed

One of the most significant developments in fibromyalgia research over the past decade has been the use of functional brain imaging to characterise the neurological abnormalities associated with the condition. Studies using SPECT (single photon emission computed tomography) and fMRI have consistently identified patterns of abnormal brain activity in people with fibromyalgia, including reduced blood flow and metabolic activity in regions involved in pain processing and modulation.

These imaging findings do two things. First, they provide objective evidence of a neurological basis for fibromyalgia, which is important for a condition that has historically been dismissed as psychosomatic. Second, they provide a measurable target for treatment, a way of assessing whether an intervention is actually changing the underlying neurology rather than simply masking symptoms.

This is the context in which the most important HBOT fibromyalgia research was conducted.

The Key Research

The most significant study of HBOT for fibromyalgia was published in 2015 in PLOS ONE by researchers at the Sagol Center for Hyperbaric Medicine and Research in Israel. The study enrolled 48 women with fibromyalgia who had been diagnosed for at least two years and had not responded adequately to conventional treatment. Participants were randomised to receive either 40 sessions of HBOT at 2.0 ATA with 100% oxygen, or a crossover control condition.

The results were notable. The HBOT group showed significant improvements in pain, tenderness, and quality of life compared to the control group. But what made the study particularly compelling was the imaging component. SPECT brain scans conducted before and after treatment showed measurable changes in brain activity in the HBOT group, with normalisation of activity in regions that had shown abnormal patterns at baseline. The symptom improvements correlated with the imaging changes.

This is meaningful for several reasons. It suggests that HBOT is not simply producing a placebo response or masking symptoms, but is producing measurable changes in the neurological mechanisms associated with fibromyalgia. It also aligns with what is known about HBOT's effects on the brain: its capacity to promote neuroplasticity, reduce neuroinflammation, and improve cerebral blood flow in hypoperfused regions.

A subsequent study by the same research group, published in 2016, examined whether the improvements were sustained after treatment ended. The findings suggested that benefits were maintained at follow-up, which is important for a condition where symptom management is typically ongoing.

What the Evidence Does Not Show

Intellectual honesty requires being equally clear about the limitations of the current evidence base.

The fibromyalgia HBOT literature is small. The 2015 PLOS ONE study, while well-designed and compelling, enrolled 48 participants. Larger, multicentre, independently replicated trials have not yet been conducted. The research has not been reproduced by independent groups at the scale that would be required to establish HBOT as a standard of care for fibromyalgia.

The study population was exclusively women, which reflects the demographic reality of fibromyalgia (it affects women at roughly three to four times the rate of men) but means the findings cannot be straightforwardly generalised to all people with the condition.

The protocol used in the research, 40 sessions at 2.0 ATA with 100% oxygen, is specific. There is no basis for assuming that a different protocol, particularly a soft-shell chamber at 1.3 ATA, would produce the same results. The mechanism that makes HBOT relevant to fibromyalgia, its effects on cerebral blood flow and neuroplasticity, depends on achieving therapeutic oxygen concentrations in plasma, which requires clinical-grade pressures and oxygen delivery.

Finally, fibromyalgia is a heterogeneous condition. Not everyone who carries the diagnosis has the same underlying neurobiology, and it is likely that some subgroups respond better to HBOT than others. The research does not yet provide clear guidance on which patients are most likely to benefit.

The Central Sensitisation Connection

Understanding why HBOT might work for fibromyalgia requires understanding the central sensitisation mechanism in more detail.

In central sensitisation, the brain's pain-processing networks become dysregulated in ways that are self-reinforcing. Chronic pain alters the structure and function of neural circuits, making them more sensitive and more reactive. This is not a psychological process in the dismissive sense that the word is sometimes used; it is a neurobiological one, involving measurable changes in synaptic connectivity, neurotransmitter systems, and the balance between excitatory and inhibitory signalling in the central nervous system.

HBOT's relevance to this mechanism operates through several pathways. The increase in dissolved plasma oxygen at clinical pressures supports the metabolic demands of neural tissue repair and remodelling. HBOT has been shown to reduce neuroinflammation, which is increasingly recognised as a component of central sensitisation. And the promotion of angiogenesis and improved cerebral blood flow addresses the hypoperfusion patterns that the imaging studies have identified in fibromyalgia patients.

None of this means HBOT is a cure for fibromyalgia. Central sensitisation, once established, is not easily reversed. But the research suggests that HBOT can produce meaningful changes in the neurological substrate of the condition, and that these changes translate into real improvements in symptoms and quality of life for at least a proportion of patients.

What People with Fibromyalgia Should Understand

If you have fibromyalgia and are considering HBOT, several things are worth understanding clearly before you proceed.

The evidence is promising but limited. The research that exists is genuinely encouraging, and the mechanistic rationale is coherent. But the evidence base is not large enough to make confident predictions about individual outcomes. Some people with fibromyalgia respond well to HBOT. Others do not. The research does not yet tell us reliably who will fall into which category.

Protocol matters considerably. The positive research was conducted at 2.0 ATA with 100% oxygen for 40 sessions. A soft-shell chamber at 1.3 ATA is a different intervention. If you are pursuing HBOT for fibromyalgia on the basis of the clinical research, you need access to a clinical-grade hard-shell chamber operated at the pressures used in that research. This has implications for where you seek treatment and what questions you ask when evaluating a facility.

A thorough clinical assessment should precede treatment. Fibromyalgia is a diagnosis of exclusion, and the symptom overlap with other conditions, including autoimmune disorders, thyroid dysfunction, sleep disorders, and mood disorders, is significant. Before pursuing HBOT, it is worth ensuring that the diagnosis is well-established and that other contributing factors have been adequately assessed. The quality of the clinical evaluation matters as much as the treatment itself.

HBOT is not a replacement for other management strategies. The evidence for HBOT in fibromyalgia is strongest when it is considered as part of a broader management approach that may include sleep optimisation, graded exercise, psychological support, and where appropriate, pharmacological management. The research does not support the idea that HBOT alone is sufficient.

Forty sessions is a significant commitment. The protocol used in the research involves 40 sessions, typically conducted daily or near-daily over eight weeks. This is a meaningful time and logistical commitment, and the cost implications are real. Understanding this upfront, and planning for it, is important.

The Broader Context: A Condition That Deserves Better

Fibromyalgia has been poorly served by conventional medicine, and the people who live with it have often been poorly served by the healthcare system more broadly. The dismissal of fibromyalgia as a psychosomatic condition, the inadequacy of most available treatments, and the tendency to offer symptom management rather than any attempt at addressing underlying mechanisms have left many patients searching for alternatives.

HBOT is not a miracle solution, and it would be dishonest to present it as one. But it is one of the few interventions that has produced both measurable neurological changes and meaningful symptom improvements in a well-designed clinical trial. For a condition where the bar for what counts as a meaningful treatment option is, frankly, not high, that is worth taking seriously.

The research needs to be replicated at larger scale. The question of which patients are most likely to benefit needs to be answered. The optimal protocol needs to be refined. These are legitimate scientific questions that remain open.

What is not open is whether the existing evidence is worth taking seriously. It is. For people with fibromyalgia who have not found adequate relief through conventional approaches, HBOT represents a genuinely evidence-informed option worth exploring, with appropriate clinical guidance and realistic expectations.